Ecarin Clotting Time is Sensitive to Heparinoids: Comparison of Two Different Techniques

Abstract

Ecarin clotting time (ECT) is currently developed for the specific monitoring of antithrombin drugs, such as hirudin, argatroban, and hirulog. Aqueous reagent and dry chemistry technology have become available for ECT monitoring of antithrombin agents. Currently, many heparinoids and heparinomimetic drugs are being developed. These agents activate heparin cofactor 11 (HCII) and primarily mediate their effects by inhibiting thrombin. Atthough the test is specific for antithrombin agents, heparin cofactor II-mediated thrombin inhibitors are capable of prolonging the ECT. In order to study the relative effects of some of these agents, ECT was measured in human plasma supplemented with PI-88 (a sutfated pentomanose ; Progen Industries Limited. Sydney, Australia), aprosulate, pentosan polysulfate, dermatan Sulfate, unfractionated heparin (UFH), and recombinant hirudin (r-hirtadin). All agents were supplemented to the citrited-pooled plasma prepared from 10 healthy volunteers at a graded dosage of 0 to 100 These techniques gave comparable results for all of the agents used (PI-88. r² = 0.99; r-hirudin, r²= 0.98, UFH. r² =0.98; dermatan sutfate, r² = 0.95; aprosulate, r² = 0.95; pentosan polysulfate, r² = 0.94). The relative anticoagulant effects of various agents used on ECT varied widely, exhibiting their potency in the following order: r-hirudin = pentosan polysulfate > dermatan sulfate > PI-88 > aprosulate > UFH. The sensitivity of ECT was adjusted by varying the concentration of the ecarin reagent. The results suggest that HCIImediated inhibition of thrombin can be detected by using ECT reagents.

Keywords

Heparinoids Ecarin clotting time Heparin cofactor II PI-88 Recombinant hirudin.

References

Pineo GF , Hull RD Thrombin inhibitors as anticoagulant agents. Curr Opin Hematol 1999;6:298.

Fareed J. , Lewis BE , Callas DD et al. Antithrombin agents: the new class of anticoagulant and antithrombotic drugs. Clin Appl Thromb Hemost 1999(suppl 1);5:S45.

Pompa JJ , Coller BS , Ohman EM , et al. Antithrombotic therapy in patients undergoing coronary angioplasty . Chest 1995;108:486S.

Zoldehelyi P. , Webster Mwi , Fuster V. , et al. Recombinant hirudin in patients with chronic stable coronary disease: safety, half-life and effect on coagualtion parameters. Circulation 1993;88:2015.

Walenga JM , Hoppensteadt D. , Koza M. , et al. Comparative studies on various assays for the laboratory evaluation of r-hirudin. Semin Thromb Hemost 1991;17:103.

Nowak G. , Bucha E. A new method for the therapeutical monitoring of hirudin. Thromb Haemost 1993;69:1306.

Nowak G. , Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 1996;22:197.

Fareed J. , Callas D. , Hoppensteadt D. , et al. Recent developments in antithrombotic agents. Exp Opin Invest Drugs 1995;4:389.

Koster A. , Hansen R. , Grauhan O. , et al. Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type-II. J Cardiothorac Vasc Anesth 2000;14: 249.

10.

Callas D. , Fareed J. Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method. Thromb Res 1996;83:463.

11.

Aspinsall GO Structural chemistry of the hemi cellulose . Adv Carbo Chem 1959;14:434.

12.

Scully MF , Weerasinge KM , Ellis V. , et al. Anticoagulant and antiheparin activities of a pentosan polysulfate . Thromb Res 1983; 36:187.

13.

Scully MF , Kakkar VV Identification of heparin cofactor 11 as the principle plasma cofactor for pentosan polysulfate (SP54). Thromb Res 1984 ;36:187.

14.

Hoppensteadt D. , Walenga JM , Fareed J. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin. Thromb Res 1990;60:191.

15.

Ofosu F. Antithrombotic mechanism of heparin and related compounds. In: Lane D , Lindahl U , eds. Heparin: Chemical and Biological Properties, Clinical Applications . London: Edward Arnold , 1989:433.

16.

Papoulias UE , Wyld PJ , Haas S. , et al. Phase I-study with aprosulate, a new synthetic anticoagulant. Thromb Res 1993;72:99.

17.

Klauser RJ , Raake W. , Meinetsberger E. , et al. Antithrombotic and anticoagulant properties of synthetic polyanions: sulfated bisaldonic acid amides. J Pharm Exp Ther 1991;259:8.

18.

Petersen TE , Roberts HR , Sottrup-Jensen L. , et al. Primary structure of hirudin, a thrombin-specific inhibitor . In: Peters H , ed. Peptides of the Biological Fluids. Oxford: Pergamon, 1976:145.

19.

Knornalik F. , Blomback B. Isolatin, biochemical and pharmacological characterization of a prothrombin activating principle from Echis carinatus venom. Naunyn Schmiedberg's Arch Pharmakol 1969;264:259.

20.

Morita T. , Iwanaga S. , Suzuki T. The mechanism of activation of bovine prothrombin by an activator isolated from Echis carinatus venom and characterization of the new active intermediates . J Biochem 1976;79:1089.

21.

Callas DD , Hoppensteadt D. , Iqbat O. , et al. Ecarin clotting time is a reliable method for the monitoring of hirudins, argatroban, efegetran and related drugs in the -therapeutic and cardiovascular indications. Ann Hematol 1996 ; I:A58.

22.

Iqbal O. , Demir M. , Hoppensteadt D. , et al. Ecarin clotting time is sensitive to heparinoids: diagnostic and clinical implications. Int Angiol 2000 ;19(suppl 1):95.